| Abstract: | Several advances have been made in the treatment of advanced non-small cell lung cancer in the last few years. Combined modality therapies utilizing chemotherapy have improved survival of patients with locally advanced disease (stage III) when compared to either radiation or surgery alone. New chemotherapeutic agents, used alone or in combination, have also made a strong impact in patients with metastatic disease (stage IV). Ongoing randomized trials will certainly define new treatment standards and hopefully improve the outcome of patients with advanced non-small cell lung cancer. |
